CY1123859T1 - Παραγωγα ν-(φαινυλσoυλφoνυλ)βενζαμiδιoυ ως αναστολεις bcl-2 - Google Patents

Παραγωγα ν-(φαινυλσoυλφoνυλ)βενζαμiδιoυ ως αναστολεις bcl-2

Info

Publication number
CY1123859T1
CY1123859T1 CY20211100032T CY211100032T CY1123859T1 CY 1123859 T1 CY1123859 T1 CY 1123859T1 CY 20211100032 T CY20211100032 T CY 20211100032T CY 211100032 T CY211100032 T CY 211100032T CY 1123859 T1 CY1123859 T1 CY 1123859T1
Authority
CY
Cyprus
Prior art keywords
benzamidium
phenylsulfonyl
bcl
inhibitors
derivatives
Prior art date
Application number
CY20211100032T
Other languages
English (en)
Inventor
Shaomeng Wang
Jianyong Chen
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of CY1123859T1 publication Critical patent/CY1123859T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Η παρούσα αποκάλυψη παρέχει ενώσεις που έχουν Χημικό Τύπο Ι-Α: και τα φαρμακευτικώς αποδεκτά άλατα και επιδιαλυτωμένα άλατα εξ αυτών, όπου τα Α, Χ1, Χ2, Χ3, R1a, R1b, Ε και = καθορίζονται ως παρατίθενται στην προδιαγραφή. Η παρούσα αποκάλυψη παρέχει επίσης και ενώσεις του Χημικού Τύπου Ι-Α για χρήση σε αγωγή μιας πάθησης, διαταραχής, ή κατάστασης αποκρινόμενης ως προς αναστολή πρωτεϊνών BcI-2 όπως είναι ο καρκίνος.
CY20211100032T 2016-08-05 2021-01-15 Παραγωγα ν-(φαινυλσoυλφoνυλ)βενζαμiδιoυ ως αναστολεις bcl-2 CY1123859T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US201762454101P 2017-02-03 2017-02-03
PCT/US2017/045428 WO2018027097A1 (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
CY1123859T1 true CY1123859T1 (el) 2022-05-27

Family

ID=59677319

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100032T CY1123859T1 (el) 2016-08-05 2021-01-15 Παραγωγα ν-(φαινυλσoυλφoνυλ)βενζαμiδιoυ ως αναστολεις bcl-2

Country Status (26)

Country Link
US (3) US10829488B2 (el)
EP (3) EP4129999A1 (el)
JP (2) JP6651180B2 (el)
KR (2) KR102376764B1 (el)
CN (2) CN110483501B (el)
AU (2) AU2017305508B2 (el)
BR (1) BR112019001666A2 (el)
CA (1) CA3031419C (el)
CY (1) CY1123859T1 (el)
DK (1) DK3494115T3 (el)
ES (1) ES2849959T3 (el)
HR (1) HRP20202073T1 (el)
HU (1) HUE053414T2 (el)
IL (2) IL264059B (el)
LT (1) LT3494115T (el)
MX (2) MX2019001391A (el)
PE (1) PE20190711A1 (el)
PH (1) PH12019500231A1 (el)
PT (1) PT3494115T (el)
RS (1) RS61821B1 (el)
RU (3) RU2744358C2 (el)
SA (1) SA519401020B1 (el)
SG (2) SG11201900135YA (el)
SI (1) SI3494115T1 (el)
WO (1) WO2018027097A1 (el)
ZA (2) ZA201900240B (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
EP4129999A1 (en) * 2016-08-05 2023-02-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
CN110546151B (zh) * 2017-04-18 2023-04-28 重庆复创医药研究有限公司 凋亡诱导剂
CA3098348A1 (en) 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 inhibitors
KR20210003731A (ko) * 2018-07-31 2021-01-12 어센테지 파마 (쑤저우) 컴퍼니 리미티드 Bcl-2 억제제와 MDM2 억제제의 병용 제품 및 질환의 예방 및/또는 치료에 있어서 이의 용도
CN110772521A (zh) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3095699A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
EP3706741A4 (en) * 2018-11-23 2022-03-30 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMPOSITION AND USE THEREOF
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
WO2021000899A1 (en) * 2019-07-02 2021-01-07 Ascentage Pharma (Suzhou) Co., Ltd. A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF
CN112294966B (zh) * 2019-07-31 2021-12-17 苏州亚盛药业有限公司 Bcl-2/Bcl-xL抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
WO2021104442A1 (en) * 2019-11-27 2021-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
TWI772992B (zh) * 2019-12-03 2022-08-01 大陸商蘇州亞盛藥業有限公司 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
WO2021110136A1 (en) * 2019-12-04 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
KR20230127372A (ko) 2019-12-06 2023-08-31 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여
EP3914596A4 (en) * 2020-03-06 2022-04-20 Ascentage Pharma (Suzhou) Co., Ltd. CRYSTALLINE FORMS OR AMORPHOUS FORMS OF N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS OR THEIR SALTS OR SOLVATES
US20230128137A1 (en) * 2020-03-12 2023-04-27 Medshine Discovery Inc. Benzo five-membered cyclic compound
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
US20230159524A1 (en) * 2020-07-01 2023-05-25 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
EP4199924A4 (en) * 2020-08-21 2024-08-28 Ascentage Pharma Suzhou Co Ltd COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATODES
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
JP2023551056A (ja) * 2020-11-25 2023-12-06 アセンテージ ファーマ(スーチョウ)カンパニー,リミティド 固体分散体、医薬製剤、その製造方法及び応用
CN114681458B (zh) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 治疗多发性硬化症的方法
JP2024504542A (ja) * 2021-02-01 2024-02-01 アセンテージ ファーマ(スーチョウ)カンパニー,リミティド Bcl-2阻害剤としてのスルホニルベンズアミド誘導体
EP4319800A1 (en) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
WO2023011488A1 (zh) 2021-08-02 2023-02-09 苏州亚盛药业有限公司 一种药物组合及其用途
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
EP4421075A1 (en) * 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein
WO2024184233A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
CN101534904B (zh) 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
CN101611154A (zh) 2006-12-04 2009-12-23 艾博特公司 用于癌症治疗的成对诊断测定
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
HUE029289T2 (en) 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2012517241A (ja) 2009-02-11 2012-08-02 アボット・ラボラトリーズ Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物
HUE027698T2 (en) 2009-05-26 2016-10-28 Abbvie Bahamas Ltd Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
MY191300A (en) 2010-11-23 2022-06-14 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
JP6141188B2 (ja) 2010-11-23 2017-06-07 アッヴィ・インコーポレイテッド アポトーシス誘導剤の塩および結晶の形態
AU2016381010B2 (en) 2015-12-30 2019-05-23 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile
EP4129999A1 (en) * 2016-08-05 2023-02-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Also Published As

Publication number Publication date
KR20190035710A (ko) 2019-04-03
MX2019001391A (es) 2019-06-06
HRP20202073T1 (hr) 2021-02-19
US20180354950A1 (en) 2018-12-13
ZA201908466B (en) 2020-05-27
ES2849959T3 (es) 2021-08-24
IL264059A (en) 2019-01-31
EP3494115A1 (en) 2019-06-12
KR102429704B1 (ko) 2022-08-04
PE20190711A1 (es) 2019-05-17
SG10201913643YA (en) 2020-03-30
RU2020134802A (ru) 2022-04-25
IL264059B (en) 2021-05-31
US11718613B2 (en) 2023-08-08
EP3494115B1 (en) 2020-10-21
SA519401020B1 (ar) 2022-03-16
BR112019001666A2 (pt) 2019-05-28
AU2021202113B2 (en) 2022-08-18
WO2018027097A1 (en) 2018-02-08
CN110483501B (zh) 2022-07-01
RU2020114660A (ru) 2020-06-19
PH12019500231A1 (en) 2019-07-29
IL282099B (en) 2022-03-01
JP7205903B2 (ja) 2023-01-17
RS61821B1 (sr) 2021-06-30
IL282099A (en) 2021-05-31
SI3494115T1 (sl) 2021-02-26
ZA201900240B (en) 2020-05-27
JP2020007311A (ja) 2020-01-16
SG11201900135YA (en) 2019-02-27
CA3031419A1 (en) 2018-02-08
EP3569601B1 (en) 2022-06-22
RU2744358C2 (ru) 2021-03-05
KR20210107170A (ko) 2021-08-31
AU2017305508A1 (en) 2019-02-07
CN109311871A (zh) 2019-02-05
CN110483501A (zh) 2019-11-22
US10829488B2 (en) 2020-11-10
PT3494115T (pt) 2021-01-15
RU2020114660A3 (el) 2020-09-15
LT3494115T (lt) 2021-01-25
US20190315739A1 (en) 2019-10-17
EP3569601A3 (en) 2019-11-27
KR102376764B1 (ko) 2022-03-18
JP6651180B2 (ja) 2020-02-19
JP2019527705A (ja) 2019-10-03
EP3569601A2 (en) 2019-11-20
US10221174B2 (en) 2019-03-05
HUE053414T2 (hu) 2021-06-28
US20210002277A1 (en) 2021-01-07
NZ750100A (en) 2021-01-29
MX2020013014A (es) 2021-02-22
CN109311871B (zh) 2020-02-28
AU2017305508B2 (en) 2021-01-07
DK3494115T3 (da) 2021-01-18
RU2722560C1 (ru) 2020-06-01
EP4129999A1 (en) 2023-02-08
AU2021202113A1 (en) 2021-05-06
CA3031419C (en) 2021-08-24

Similar Documents

Publication Publication Date Title
CY1123859T1 (el) Παραγωγα ν-(φαινυλσoυλφoνυλ)βενζαμiδιoυ ως αναστολεις bcl-2
CY1123666T1 (el) Φαρμακευτικες ενωσεις
CY1123395T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
CY1123353T1 (el) Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CY1124359T1 (el) Ενωσεις και συνθεσεις για ρυθμιση δραστικοτητων κινασης μεταλλακτικου egfr
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1119466T1 (el) Παραγωγα ιμιδαζοθειαδιαζολης και ιμιδαζοπυραζινης ως αναστολεις του ενεργοποιουμενου απο πρωτεαση υποδοχεα 4 (par 4) για αγωγη συσσωματωσης αιμοπεταλιων
CY1125068T1 (el) Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CY1124918T1 (el) Ρυθμιστες ccr2
CY1124552T1 (el) Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4
CY1120619T1 (el) Χημικες οντοτητες
CY1122549T1 (el) Παραγωγα καρβαζολης
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
EA201790317A1 (ru) Ингибиторы smyd
CY1121972T1 (el) Mono- ή διυποκατεστημενα ινδολια ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
CY1117712T1 (el) Adcs δουοκαρμυκινης για χρηση στη θεραπεια ενδομητριου καρκινου
CY1126109T1 (el) Αναστολεις toy trpc6
BR112019003897A2 (pt) aminopirimidinas como inibidores de alk